drugset / Trial / NCT00700986

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

NCT00700986

Phase 1 Completed 12 enrolled AstraZeneca
RandomizedCrossoverDouble-blind

Summary

The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina

Timeline

Start
2008-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9056 Small molecule 800 mg Oral

Indications